ALC Inhibitor

Ross is going to talk about optimal identification of a positive disease and some of the issues related to testing. We're going to get into the issue of choice of ALC inhibitor, that's going to be one of the more interesting things. I just want to point out a really great pro and con debate and controversies in thoracic oncology,. Ross took the anti-luralatinib and a couple other people did the pro- luralatinib. If you want to see a lot of the discussions that we'll flesh out, check out those two papers.